P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS. (23rd June 2022)

Record Type:: Journal Article
Title:: P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS. (23rd June 2022)
Main Title:: P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
Authors:: Harrison, C.
Rampal, R. K.
Gupta, V.
Verstovsek, S.
Talpaz, M.
Kiladjian, J.-J.
Mesa, R.
Kuykendall, A.
Vannucchi, A.
Palandri, F.
Grosicki, S.
Devos, T.
Jourdan, E.
Wondergem, M. J.
Al-Ali, H. K.
Buxhofer-Ausch, V.
Alvarez-Larrán, A.
Akhani, S.
Muñoz-Carerras, R.
Sheykin, Y.
Colak, G.
Harris, M.
Mascarenhas, J.
Abstract:
Is Part Of:: HemaSphere. Volume 6(2022)Supplement 3
Journal:: HemaSphere
Issue:: Volume 6(2022)Supplement 3
Issue Display:: Volume 6, Issue 3 (2022)
Year:: 2022
Volume:: 6
Issue:: 3
Issue Sort Value:: 2022-0006-0003-0000
Page Start:: 920
Page End:: 921
Publication Date:: 2022-06-23
Subjects:: Hematology -- Periodicals
616.15005
Journal URLs:: https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:: 10.1097/01.HS9.0000846988.26018.ea ↗
Languages:: English
ISSNs:: 2572-9241
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 22737.xml